Healthcare Industry News: Talecris Biotherapeutics
News Release - September 25, 2013
Cubist Pharmaceuticals Appoints Kenneth Martin to Board of DirectorsLEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Cubist Pharmaceuticals, Inc. (CBST) today announced the appointment of Kenneth J. Martin to its Board of Directors. Mr. Martin most recently served as the Chief Financial Officer and Vice Chairman of Wyeth and currently serves on the Board of WABCO Holdings, Inc.
“Ken Martin has an exceptional mix of global finance, industry and leadership expertise that will be a valued asset to Cubist, and we are thrilled to have him join our Board,” said Ken Bate, non-executive Chairman of the Board of Directors of Cubist. “Importantly, Ken’s experience at Wyeth gives him an important perspective as Cubist begins its next, exciting chapter focused on global growth and continuing to drive significant shareholder value.”
Mr. Martin served as the Chief Financial Officer and Vice Chairman of Wyeth (formerly American Home Products) from 2000 to 2007, before retiring in 2007. Mr. Martin joined American Home Products in 1984 and held the positions of Senior Vice President of Finance, Executive Vice President and President for American Home Food Products. He also served in a variety of senior roles for Whitehall-Robins Healthcare, and became the Company’s President in 1997. In 1998 he was named Senior Vice President and Chief Financial Officer of Wyeth-Ayerst Pharmaceuticals, and in 2000 he was named Wyeth’s Senior Vice President and Chief Financial Officer. Since 2007, Mr. Martin has served as a member of the Board of Directors of WABCO Holdings, Inc., a leading global supplier of technologies and control systems for the safety and efficiency of commercial vehicles. He previously served as a member of the board of directors of Talecris Biotherapeutics Holdings Corp from 2007 to 2011. He earned his BBA in Accounting from Hofstra University.
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding our plans to expand globally and continue driving shareholder value, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include: our ability to successfully develop, gain marketing approval for and commercially launch our product candidates for their planned indications and on the timelines that we expect; our ability to discover, in-license or acquire new products and product candidates; our ability to achieve and manage our growth in our business; and those additional factors discussed in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.
Source: Cubist Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.